Prognostic significance of tumor-associated trypsin inhibitor (TATI) and human chorionic gonadotropin-β (hCGβ) in patients with hepatocellular carcinoma

References

• Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2008;127:2893–917.
   Web of Science ®Google Scholar
• Sherman M. Hepatocellular carcinoma: epidemiology, surveillance, and diagnosis. Semin Liver Dis 2010;30:3–16.
   PubMed Web of Science ®Google Scholar
• Alazawi W, Cunningham M, Dearden J, Foster GR. Systematic review: outcome of compensated cirrhosis due to chronic hepatitis C infection. Aliment Pharmacol Ther 2010;32:344–55.
   PubMed Web of Science ®Google Scholar
• Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011;61:69–90.
   PubMed Web of Science ®Google Scholar
• EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 2012;56:908–43.
   PubMed Web of Science ®Google Scholar
• Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet 2003;362:1907–17.
   PubMed Web of Science ®Google Scholar
• Llovet JM, Fuster J, Bruix J. Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation. Hepatology 1999;30:1434–40.
   PubMed Web of Science ®Google Scholar
• Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet 2012; 379:1245–55.
   PubMed Web of Science ®Google Scholar
• Poon RT, Fan ST, Ng IO, Lo CM, Liu CL, Wong J. Different risk factors and prognosis for early and late intrahepatic recurrence after resection of hepatocellular carcinoma. Cancer 2000;89:500–7.
   PubMed Web of Science ®Google Scholar
• Fukuda S, Itamoto T, Nakahara H, Kohashi T, Ohdan H, Hino H, et al. Clinicopathologic features and prognostic factors of resected solitary small-sized hepatocellular carcinoma. Hepatogastroenterology 2005;52:1163–7.
   PubMedGoogle Scholar
• Befeler AS, Di Bisceglie AM. Hepatocellular carcinoma: diagnosis and treatment. Gastroenterology 2002;122:1609–19.
   PubMed Web of Science ®Google Scholar
• Behne T, Copur MS. Biomarkers for hepatocellular carcinoma. Int J Hepatol 2012;2012:859076.
   PubMedGoogle Scholar
• Louhimo J, Finne P, Alfthan H, Stenman UH, Haglund C. Combination of HCGbeta, CA 19-9 and CEA with logistic regression improves accuracy in gastrointestinal malignancies. Anticancer Res 2002;22:1759–64.
   PubMed Web of Science ®Google Scholar
• Stenman UH, Alfthan H, Hotakainen K. Human chorionic gonadotropin in cancer. Clin Biochem 2004;37:549–61.
   PubMed Web of Science ®Google Scholar
• Paju A, Stenman UH. Biochemistry and clinical role of trypsinogens and pancreatic secretory trypsin inhibitor. Crit Rev Clin Lab Sci 2006;43:103–42.
   PubMed Web of Science ®Google Scholar
• Stenman UH. Tumor-associated trypsin inhibitor. Clin Chem 2002;48:1206–9.
   PubMed Web of Science ®Google Scholar
• Lempinen M, Stenman UH, Puolakkainen P, Hietaranta A, Haapiainen R, Kemppainen E. Sequential changes in pancreatic markers in acute pancreatitis. Scand J Gastroenterol 2003;38:666–75.
   PubMedGoogle Scholar
• Ogawa M, Shibata T, Niinobu T, Uda K, Takata N, Mori T. Serum pancreatic secretory trypsin inhibitor (PSTI) in patients with inflammatory diseases. Adv Exp Med Biol 1988;240:505–8.
   PubMedGoogle Scholar
• Marshall A, Lukk M, Kutter C, Davies S, Alexander G, Odom DT. Global Gene expression profiling reveals SPINK1 as a potential hepatocellular carcinoma marker. PLoS ONE 2013;8:e59459.
   PubMed Web of Science ®Google Scholar
• Ohmachi Y, Murata A, Matsuura N, Yasuda T, Monden M, Mori T, et al. Specific expression of the pancreatic-secretory-trypsin-inhibitor (PSTI) gene in hepatocellular carcinoma. Int J Cancer 1993;55:728–34.
   PubMed Web of Science ®Google Scholar
• Pasanen PA, Eskelinen M, Partanen K, Pikkarainen P, Penttila I, Alhava E. Multivariate analysis of six serum tumor markers (CEA, CA 50, CA 242, TPA, TPS, TATI) and conventional laboratory tests in the diagnosis of hepatopancreatobiliary malignancy. Anticancer Res 1995;15:2731–7.
   PubMed Web of Science ®Google Scholar
• Llovet JM, Fuster J, Bruix J. The Barcelona approach: diagnosis, staging, and treatment of hepatocellular carcinoma. Liver Transpl 2004;10:S115–20.
   PubMedGoogle Scholar
• Osman S, Turpeinen U, Itkonen O, Stenman UH. Optimization of a time-resolved immunofluorometric assay for tumor-associated trypsin inhibitor (TATI) using the streptavidin-biotin system. J Immunol Methods 1993;161:97–106.
   PubMed Web of Science ®Google Scholar
• Alfthan H, Schroder J, Fraser R, Koskimies A, Halila H, Stenman UH. Choriogonadotropin and its beta subunit separated by hydrophobic-interaction chromatography and quantified in serum during pregnancy by time-resolved immunofluorometric assays. Clin Chem 1988;34:1758–62.
   PubMed Web of Science ®Google Scholar
• Alfthan H, Haglund C, Dabek J, Stenman UH. Concentrations of human choriogonadotropin, its beta-subunit, and the core fragment of the beta-subunit in serum and urine of men and nonpregnant women. Clin Chem 1992;38:1981–7.
   PubMed Web of Science ®Google Scholar
• Suonpaa MU, Lavi JT, Hemmila IA, Lovgren TN. A new sensitive assay of human alpha-fetoprotein using time-resolved fluorescence and monoclonal antibodies. Clin Chim Acta 1985;145:341–8.
   PubMed Web of Science ®Google Scholar
• Singhal A, Jayaraman M, Dhanasekaran DN, Kohli V. Molecular and serum markers in hepatocellular carcinoma: predictive tools for prognosis and recurrence. Crit Rev Oncol Hematol 2012;82:116–40.
   PubMed Web of Science ®Google Scholar
• Santambrogio R, Opocher E, Costa M, Barabino M, Zuin M, Bertolini E, et al. Hepatic resection for "BCLC stage A" hepatocellular carcinoma. The prognostic role of alpha-fetoprotein. Ann Surg Oncol 2012;19:426–34.
   PubMedGoogle Scholar
• A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients: the Cancer of the Liver Italian Program (CLIP) investigators. Hepatology 1998;28:751–5.
   PubMed Web of Science ®Google Scholar
• Murray MJ, Nicholson JC. Alpha-Fetoprotein. Arch Dis Child Educ Pract Ed 2011;96:141–7.
   PubMedGoogle Scholar
• Saffroy R, Pham P, Reffas M, Takka M, Lemoine A, Debuire B. New perspectives and strategy research biomarkers for hepatocellular carcinoma. Clin Chem Lab Med 2007;45:1169–79.
   PubMed Web of Science ®Google Scholar
• Stenman UH, Huhtala ML, Koistinen R, Seppala M. Immunochemical demonstration of an ovarian cancer-associated urinary peptide. Int J Cancer 1982;30:53–7.
   PubMed Web of Science ®Google Scholar
• Kazal LA, Spicer DS, Brahinsky RA. Isolation of crystalline trypsin inhibitor-anticoagulant protein from pancreas. J Am Chem Soc 1948;70:3034–40.
   PubMed Web of Science ®Google Scholar
• Lamontagne J, Pinkerton M, Block TM, Lu X. Hepatitis B and hepatitis C virus replication upregulates serine protease inhibitor Kazal, resulting in cellular resistance to serine protease-dependent apoptosis. J Virol 2010;84:907–17.
   PubMed Web of Science ®Google Scholar
• Jonsson P, Linder C, Genell S, Ohlsson K. Extrapancreatic origin of the pancreatic secretory trypsin inhibitor as an acute-phase reactant. Pancreas 1996;12:303–7.
   PubMedGoogle Scholar
• Yamamoto T, Nakamura Y, Nishide J, Emi M, Ogawa M, Mori T, et al. Molecular cloning and nucleotide sequence of human pancreatic secretory trypsin inhibitor (PSTI) cDNA. Biochem Biophys Res Commun 1985;132:605–12.
   PubMedGoogle Scholar
• Lee YC, Pan HW, Peng SY, Lai PL, Kuo WS, Ou YH, et al. Overexpression of tumour-associated trypsin inhibitor (TATI) enhances tumour growth and is associated with portal vein invasion, early recurrence and a stage-independent prognostic factor of hepatocellular carcinoma. Eur J Cancer 2007;43:736–44.
   PubMed Web of Science ®Google Scholar
• Lukkonen A, Lintula S, von Boguslawski K, Carpen O, Ljungberg B, Landberg G, et al. Tumor-associated trypsin inhibitor in normal and malignant renal tissue and in serum of renal-cell carcinoma patients. Int J Cancer 1999;83:486–90.
   PubMed Web of Science ®Google Scholar
• Paju A, Vartiainen J, Haglund C, Itkonen O, von Boguslawski K, Leminen A, et al. Expression of trypsinogen-1, trypsinogen-2, and tumor-associated trypsin inhibitor in ovarian cancer: prognostic study on tissue and serum. Clin Cancer Res 2004;10:4761–8.
   PubMed Web of Science ®Google Scholar
• Kelloniemi E, Rintala E, Finne P, Stenman UH. Tumor-associated trypsin inhibitor as a prognostic factor during follow-up of bladder cancer. Urology 2003;62:249–53.
   PubMed Web of Science ®Google Scholar
• Koivunen E, Ristimaki A, Itkonen O, Osman S, Vuento M, Stenman UH. Tumor-associated trypsin participates in cancer cell-mediated degradation of extracellular matrix. Cancer Res 1991;51:2107–12.
   PubMed Web of Science ®Google Scholar
• Butler SA, Ikram MS, Mathieu S, Iles RK. The increase in bladder carcinoma cell population induced by the free beta subunit of human chorionic gonadotrophin is a result of an anti-apoptosis effect and not cell proliferation. Br J Cancer 2000;82:1553–6.
   PubMed Web of Science ®Google Scholar
• Carpelan-Holmstrom M, Haglund C, Lundin J, Alfthan H, Stenman UH, Roberts PJ. Independent prognostic value of preoperative serum markers CA 242, specific tissue polypeptide antigen and human chorionic gonadotrophin beta, but not of carcinoembryonic antigen or tissue polypeptide antigen in colorectal cancer. Br J Cancer 1996;74:925–9.
   PubMed Web of Science ®Google Scholar
• Webb A, Scott-Mackie P, Cunningham D, Norman A, Andreyev J, O'Brien M, et al. The prognostic value of serum and immunohistochemical tumour markers in advanced gastric cancer. Eur J Cancer 1996;32A:63–8.
   PubMed Web of Science ®Google Scholar
• Louhimo J, Nordling S, Alfthan H, von Boguslawski K, Stenman UH, Haglund C. Specific staining of human chorionic gonadotropin beta in benign and malignant gastrointestinal tissues with monoclonal antibodies. Histopathology 2001;38:418–24.
   PubMed Web of Science ®Google Scholar
• Syrigos KN, Fyssas I, Konstandoulakis MM, Harrington KJ, Papadopoulos S, Milingos N, et al. Beta human chorionic gonadotropin concentrations in serum of patients with pancreatic adenocarcinoma. Gut 1998;42:88–91.
   PubMedGoogle Scholar
• Lempinen M, Isoniemi H, Makisalo H, Nordin A, Halme L, Arola J, et al. Enhanced detection of cholangiocarcinoma with serum trypsinogen-2 in patients with severe bile duct strictures. J Hepatol 2007;47:677–83.
   PubMed Web of Science ®Google Scholar
• Nakanuma Y, Unoura M, Noto H, Ohta G. Human chorionic gonadotropin in primary liver carcinoma in adults. An immunohistochemical study. Virchows Arch A Pathol Anat Histopathol 1986;409:365–73.
   PubMedGoogle Scholar